Medtronic Launches World’s First 7-Day Wear Infusion Set to Reduce Burden for People with Diabetes

美敦力推出全球首款7天佩戴输液器为糖尿病患者减负

2021-04-14 00:00:00 hitconsultant

本文共416个字,阅读需2分钟

– has announced the launch of the world’s first and only infusion set that can be worn for up to seven days (instead of the typical three) in select European countries. The infusion set is responsible for delivering insulin from the pump into the body. This new infusion set is compatible with all MiniMed™ 600 and 700 series insulin pumps. – It’s recommended that typical insulin infusion sets be changed every three days, whereas the glucose sensor (which is worn to take glucose readings every 5 minutes and deliver that information to the pump) is changed every seven days. Now, with this advanced infusion set technology, people on insulin pump therapy can change their glucose sensor and infusion set at the same time each week, allowing patients to stay on pump therapy longer with fewer interruptions, while also reducing the mental burden of tracking site changes. – Type 1 is a burdensome disease that requires constant monitoring of glucose levels, food intake and insulin pump management by those impacted. Advances in technology like this serve as a positive step in minimizing the many burdens people face in managing this disease. – In the United States, the Medtronic Extended infusion set is investigational use only and not approved for sale or distribution. The set is now commercially available in select European countries, starting with Finland and Belgium. Through a phased approach, other European countries will follow during 2021.
-宣布在欧洲选定的国家推出世界上第一个也是唯一一个可以佩戴长达七天(而不是通常的三天)的输液器。输液器负责将胰岛素从泵输送到体内。这种新型输液器与所有最小化™600和700系列胰岛素泵兼容。-建议典型的胰岛素输液器每三天更换一次,而葡萄糖传感器(每5分钟佩戴一次,以获取葡萄糖读数,并将该信息传递给泵)每七天更换一次。现在,有了这种先进的输液器技术,胰岛素泵治疗的人每周可以同时更换葡萄糖传感器和输液器,让患者在泵治疗上停留的时间更长,中断更少,同时也减轻了追踪部位变化的精神负担。-1型是一种累赘性疾病,需要对受影响者的血糖水平、食物摄入和胰岛素泵管理进行持续监测。这类技术的进步是一个积极的步骤,可以最大限度地减轻人们在控制这种疾病方面所面临的诸多负担。-在美国,美敦力加长输液器仅用于调查用途,未批准销售或分销。这套设备现在已经在一些欧洲国家开始商用,首先是芬兰和比利时。通过分阶段的方式,其他欧洲国家将在2021年期间效仿。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文